5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Gada, Hemal; Kirtane, Ajay J; NEWMAN, WILLIAM A; Sanz, Mark; Hermiller, James B.; Mahaffey, Kenneth W.; Cutlip, Donald E; Sudhir, Krishnankutty; Hou, Liming; Koo, Kai; Stone, Gregg W.

doi:10.1016/j.jcin.2013.07.009

Record: found
Abstract: found
Article: not found

5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).

Author(s): Hemal Gada ¹ , Ajay J Kirtane ¹ , William Newman ² , Mark Sanz ³ , James B Hermiller ⁴ , Kenneth W Mahaffey ⁵ , Donald E Cutlip ⁶ , Krishnankutty Sudhir ⁷ , Liming Hou ⁷ , Kai Koo ⁷ , Gregg W Stone ⁸

Publication date (Electronic): Dec 2013

Journal: JACC. Cardiovascular interventions

Keywords: DES, EES, MACE, PES, TLF, TLR, TVF, coronary artery disease, drug-eluting stent(s), everolimus-eluting stent(s), in-stent restenosis, major adverse cardiac event(s), paclitaxel-eluting stent(s), stent thrombosis, target lesion failure, target lesion revascularization, target vessel failure

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This study sought to evaluate the long-term safety and efficacy of everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES) in patients with obstructive coronary artery disease.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JACC Cardiovasc Interv

Title: JACC. Cardiovascular interventions

ISSN (Electronic): 1876-7605

ISSN (Print): 1936-8798

Publication date (Electronic): Dec 2013

Volume: 6

Issue: 12

Affiliations

[1 ] Columbia University Medical Center/New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York.

[2 ] Wake Medical Center, Raleigh, North Carolina.

[3 ] St. Patrick Hospital, Missoula, Montana.

[4 ] The Heart Center of Indiana, Indianapolis, Indiana.

[5 ] Duke Clinical Research Institute, Durham, North Carolina.

[6 ] Harvard Clinical Research Institute, Boston, Massachusetts.

[7 ] Abbott Vascular, Santa Clara, California.

[8 ] Columbia University Medical Center/New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York. Electronic address: gs2184@columbia.edu.

Article

Publisher Item ID: S1936-8798(13)01445-3

DOI: 10.1016/j.jcin.2013.07.009

PubMed ID: 24239202

SO-VID: 28202e07-6b83-40cf-a521-2991a5a66323

History

Keywords: DES,EES,MACE,PES,TLF,TLR,TVF,coronary artery disease,drug-eluting stent(s),everolimus-eluting stent(s),in-stent restenosis,major adverse cardiac event(s),paclitaxel-eluting stent(s),stent thrombosis,target lesion failure,target lesion revascularization,target vessel failure

Read this article at

Abstract

Related collections

Cardiovascular Innovations and Applications

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 4

Cited by 46